Floatz logo

Anti-Muc1 Car-T Cells

Advanced Esophageal Cancer

The First Affiliated Hospital of Guangdong Pharmaceutical UniversityCell therapyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

131 Active assets in the Advanced Esophageal Cancer cohort.

Asset / SponsorPhaseRating
Tisotumab Vedotin
Seagen Inc.
Phase 2BB
FLUOROURACILUM
Merck Sharp & Dohme LLC
Phase 4BB
Benadryl
Ciusss de L'Est de l'Île de Montréal
Phase 3B
Cyclophosphamide
Sutro Biopharma, Inc.
Phase 3B
Pembrolizumab
Essen Biotech
Phase 3B

View all 50 →

Same molecule, other indications

Anti-Muc1 Car-T Cells is also rated in:

brain gliomaDormant
CCC
Indicative ·
48 / 100
View asset →
Lung Neoplasm MalignantDormant
CCC
Indicative ·
48 / 100
View asset →
gastric carcinomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →